Trade AstraZeneca PLC - GBP - AZNl CFD

Add to favourite

109.07

0.83%

1.22

Low: 108.53

High: 109.9

Market Trading Hours* (UTC) Opens on Friday at 07:00

Mon - Fri: 07:00 - 11:00 11:03 - 15:30

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

1.22

Long position overnight fee

-0.02529%

Short position overnight fee

0.003373%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

GBP

Margin

Stock exchange

United Kingdom of Great Britain and Northern Ireland

Commission on trade

*Information provided by Capital.com

AstraZeneca PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	108.17
Open*	109.53
1-Year Change*	-7.35%
Day's Range*	108.53 - 109.9
52 wk Range	97.78-123.92
Average Volume (10 days)	2.37M
Average Volume (3 months)	41.29M
Market Cap	161.29B
P/E Ratio	34.98
Shares Outstanding	1.55B
Revenue	35.41B
EPS	2.97
Dividend (Yield %)	2.24885
Beta	0.32
Next Earnings Date	Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	109.07	-0.08	-0.07%	109.15	110.02	108.15
Apr 17, 2024	108.17	0.26	0.24%	107.91	109.35	107.63
Apr 16, 2024	108.67	1.22	1.14%	107.45	109.53	107.21
Apr 15, 2024	109.98	0.46	0.42%	109.52	110.62	109.17
Apr 12, 2024	110.50	0.84	0.77%	109.66	111.72	109.41
Apr 11, 2024	109.63	1.36	1.26%	108.27	110.70	107.95
Apr 10, 2024	107.11	1.04	0.98%	106.07	107.37	105.89
Apr 9, 2024	106.67	0.86	0.81%	105.81	106.99	105.35
Apr 8, 2024	105.91	0.10	0.09%	105.81	106.21	104.89
Apr 5, 2024	105.87	0.86	0.82%	105.01	106.41	105.01
Apr 4, 2024	107.03	1.52	1.44%	105.51	108.33	105.39
Apr 3, 2024	105.29	0.90	0.86%	104.39	105.75	104.05
Apr 2, 2024	106.11	-1.62	-1.50%	107.73	107.99	104.41
Mar 28, 2024	106.77	1.44	1.37%	105.33	107.65	105.33
Mar 27, 2024	107.17	3.20	3.08%	103.97	107.35	103.97
Mar 26, 2024	104.23	1.60	1.56%	102.63	104.25	102.63
Mar 25, 2024	103.01	-0.78	-0.75%	103.79	104.55	103.01
Mar 22, 2024	103.81	0.04	0.04%	103.77	105.33	103.33
Mar 21, 2024	103.17	1.62	1.60%	101.55	104.35	101.11
Mar 20, 2024	101.01	-0.28	-0.28%	101.29	102.25	101.01

AstraZeneca PLC - GBP Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 06:00	Country GB	Event Q1 2024 AstraZeneca PLC Earnings Release Q1 2024 AstraZeneca PLC Earnings Release Forecast - Previous -
Time (UTC) 10:45	Country GB	Event Q1 2024 AstraZeneca PLC Earnings Call Q1 2024 AstraZeneca PLC Earnings Call Forecast - Previous -
Friday, April 26, 2024
Time (UTC) 13:30	Country GB	Event AstraZeneca PLC Annual Shareholders Meeting AstraZeneca PLC Annual Shareholders Meeting Forecast - Previous -
Monday, April 29, 2024
Time (UTC) 10:59	Country GB	Event AstraZeneca PLC Stewardship Roadshow AstraZeneca PLC Stewardship Roadshow Forecast - Previous -
Tuesday, May 7, 2024
Time (UTC) 10:59	Country GB	Event AstraZeneca PLC at JPMorgan ESG Series Fireside Chat AstraZeneca PLC at JPMorgan ESG Series Fireside Chat Forecast - Previous -
Tuesday, May 21, 2024
Time (UTC) 09:00	Country GB	Event AstraZeneca PLC Investor Day AstraZeneca PLC Investor Day Forecast - Previous -
Friday, May 31, 2024
Time (UTC) 10:59	Country GB	Event AstraZeneca PLC at Barclays Hearing Out Healthcare Fireside Chat AstraZeneca PLC at Barclays Hearing Out Healthcare Fireside Chat Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	44351	37417	26617	24384	22090
Revenue	44351	37417	26617	24384	22090
Cost of Revenue, Total	8649	9542	5270	4824	4246
Gross Profit	35702	27875	21347	19560	17844
Total Operating Expense	40594	36361	21455	21460	18703
Selling/General/Admin. Expenses, Total	13512	11519	9338	8964	8479
Research & Development	9612	8519	6094	5320	5266
Depreciation / Amortization	4094	3044	1897	1812	1945
Unusual Expense (Income)	5071	3846	-763	863	-953
Other Operating Expenses, Total	-344	-109	-381	-323	-280
Operating Income	3757	1056	5162	2924	3387
Interest Income (Expense), Net Non-Operating	-815	-819	-716	-766	-775
Other, Net	-441	-502	-530	-610	-619
Net Income Before Taxes	2501	-265	3916	1548	1993
Net Income After Taxes	3293	115	3144	1227	2050
Minority Interest	-5	-3	52	108	105
Net Income Before Extra. Items	3288	112	3196	1335	2155
Net Income	3288	112	3196	1335	2155
Income Available to Common Excl. Extra. Items	3288	112	3196	1335	2155
Income Available to Common Incl. Extra. Items	3288	112	3196	1335	2155
Dilution Adjustment			0		0
Diluted Net Income	3288	112	3196	1335	2155
Diluted Weighted Average Shares	1560	1427	1313	1301	1267
Diluted EPS Excluding Extraordinary Items	2.10769	0.07849	2.43412	1.02613	1.70087
Dividends per Share - Common Stock Primary Issue	2.89361	2.84245	2.83031	2.89446	2.74532
Diluted Normalized EPS	4.04679	2.22705	1.88804	1.48501	0.85399
Interest Expense (Income) - Net Operating				0	0
Total Extraordinary Items

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	11416	10879	11207	10982	10771
Revenue	11416	10879	11207	10982	10771
Cost of Revenue, Total	1925	1782	2417	2118	1904
Gross Profit	9491	9097	8790	8864	8867
Total Operating Expense	8960	8330	10113	9737	10232
Selling/General/Admin. Expenses, Total	3592	3196	3469	3353	3340
Research & Development	2570	2299	2525	2357	2431
Depreciation / Amortization	952	954	1034	979	983
Unusual Expense (Income)	-285	379	641	1002	1298
Other Operating Expenses, Total	206	-280	27	-72	276
Operating Income	2456	2549	1094	1245	539
Interest Income (Expense), Net Non-Operating	-368	-287	-316	-323	-292
Net Income Before Taxes	2088	2262	778	922	247
Net Income After Taxes	1820	1804	902	1642	360
Minority Interest	-2	-1	-1	-2	0
Net Income Before Extra. Items	1818	1803	901	1640	360
Net Income	1818	1803	901	1640	360
Income Available to Common Excl. Extra. Items	1818	1803	901	1640	360
Income Available to Common Incl. Extra. Items	1818	1803	901	1640	360
Dilution Adjustment
Diluted Net Income	1818	1803	901	1640	360
Diluted Weighted Average Shares	1560	1560	1560	1559	1560
Diluted EPS Excluding Extraordinary Items	1.16538	1.15577	0.57756	1.05196	0.23077
Dividends per Share - Common Stock Primary Issue	0.91215	0	1.9694	0	0.93017
Diluted Normalized EPS	1.00614	1.34953	0.90705	0.99743	0.80833

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	22593	26244	19544	15563	15591
Cash and Short Term Investments	6405	6398	7992	6218	5680
Cash	1411	1461	1182	755	893
Cash & Equivalents	4755	4868	6650	4614	3938
Short Term Investments	239	69	160	849	849
Total Receivables, Net	9923	8795	5651	5181	4345
Accounts Receivable - Trade, Net	7508	6324	3956	3813	2995
Total Inventory	4699	8983	4024	3193	2890
Prepaid Expenses	1329	1512	1735	865	1436
Other Current Assets, Total	237	556	142	106	1240
Total Assets	96483	105363	66729	61377	60651
Property/Plant/Equipment, Total - Net	9449	10171	8917	8335	7421
Property/Plant/Equipment, Total - Gross	17192	18495	17110	15852	14639
Accumulated Depreciation, Total	-7743	-8324	-8193	-7517	-7218
Goodwill, Net	19820	19997	11845	11668	11707
Intangibles, Net	39307	42387	20947	20833	21959
Long Term Investments	1142	1237	1147	1459	922
Note Receivable - Long Term	592	504	325	348	515
Other Long Term Assets, Total	3580	4823	4004	3171	2536
Total Current Liabilities	26293	22594	20307	18117	16292
Accounts Payable	2550	2824	2350	1774	1720
Accrued Expenses	8303	8079	4994	5085	5148
Notes Payable/Short Term Debt	261	294	370	154	160
Current Port. of LT Debt/Capital Leases	5281	1599	2016	1856	1594
Other Current Liabilities, Total	9898	9798	10577	9248	7670
Total Liabilities	59446	66095	51107	48250	48183
Total Long Term Debt	23690	28888	17994	16217	17359
Long Term Debt	22965	28134	17505	15730	17359
Capital Lease Obligations	725	754	489	487	0
Deferred Income Tax	2944	6206	2918	2490	3286
Minority Interest	21	19	16	1469	1576
Other Liabilities, Total	6498	8388	9872	9957	9670
Total Equity	37037	39268	15622	13127	12468
Common Stock	387	387	328	328	317
Additional Paid-In Capital	35155	35126	7971	7941	4427
Retained Earnings (Accumulated Deficit)	1495	3755	7323	4858	7724
Total Liabilities & Shareholders’ Equity	96483	105363	66729	61377	60651
Total Common Shares Outstanding	1549.8	1549.4	1312.67	1312.14	1267.04

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	22501	22839	22266	22593	20224
Cash and Short Term Investments	5115	5812	6462	6405	4898
Cash & Equivalents	4871	5664	6232	6166	4458
Short Term Investments	244	148	230	239	440
Total Receivables, Net	11997	11932	10797	11252	10061
Accounts Receivable - Trade, Net	11300	11092	10289	10521	9336
Total Inventory	5292	5051	4967	4699	5078
Other Current Assets, Total	97	44	40	237	187
Total Assets	96086	96543	96687	96483	94185
Property/Plant/Equipment, Total - Net	9700	9624	9599	9449	9227
Goodwill, Net	19939	19960	20001	19820	19707
Intangibles, Net	37687	38326	39291	39307	39585
Long Term Investments	1290	1143	1234	1142	1102
Note Receivable - Long Term	761	752	682	835	792
Other Long Term Assets, Total	4208	3899	3614	3337	3548
Total Current Liabilities	28588	26375	24860	26293	24850
Payable/Accrued	20542	19738	19210	19040	17694
Notes Payable/Short Term Debt	331	271	568	261	584
Current Port. of LT Debt/Capital Leases	5276	4516	3289	5281	5034
Other Current Liabilities, Total	2439	1850	1793	1711	1538
Total Liabilities	58889	59151	60898	59446	59051
Total Long Term Debt	22969	25051	27646	23690	23681
Long Term Debt	22225	24329	26916	22965	23013
Capital Lease Obligations	744	722	730	725	668
Deferred Income Tax	2752	2800	2795	2944	3479
Minority Interest	24	24	22	21	20
Other Liabilities, Total	4556	4901	5575	6498	7021
Total Equity	37197	37392	35789	37037	35134
Common Stock	387	387	387	387	387
Additional Paid-In Capital	35166	35163	35159	35155	35137
Retained Earnings (Accumulated Deficit)	1644	1842	243	1495	-390
Total Liabilities & Shareholders’ Equity	96086	96543	96687	96483	94185
Total Common Shares Outstanding	1549.91	1549.88	1549.85	1549.8	1549.51

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	2501	-265	3916	1548	1993
Cash From Operating Activities	9808	5963	4799	2969	2618
Cash From Operating Activities	5480	6530	3149	3762	3753
Non-Cash Items	542	141	-332	-103	-1276
Cash Taxes Paid	1623	1743	1562	1118	537
Cash Interest Paid	849	721	733	774	676
Changes in Working Capital	1285	-443	-1934	-2238	-1852
Cash From Investing Activities	-2960	-11058	-285	-657	963
Capital Expenditures	-2571	-2200	-2606	-2460	-1371
Other Investing Cash Flow Items, Total	-389	-8858	2321	1803	2334
Cash From Financing Activities	-6823	3649	-2203	-1765	-2044
Financing Cash Flow Items	-1047	-178	-101	4	-67
Total Cash Dividends Paid	-4364	-3856	-3572	-3592	-3484
Issuance (Retirement) of Stock, Net	29	29	30	3525	34
Issuance (Retirement) of Debt, Net	-1441	7654	1440	-1702	1473
Foreign Exchange Effects	-80	-62	12	5	-38
Net Change in Cash	-55	-1508	2323	552	1499

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	2262	2501	1723	800	553
Cash From Operating Activities	3133	9808	7410	4480	3232
Cash From Operating Activities	1502	5480	4000	2666	1309
Non-Cash Items	-391	542	172	15	-12
Cash Taxes Paid	225	1623	1335	1006	228
Cash Interest Paid	257	849	608	386	194
Changes in Working Capital	-240	1285	1515	999	1382
Cash From Investing Activities	-1246	-2960	-2711	-968	-168
Capital Expenditures	-1470	-2571	-2017	-906	-363
Other Investing Cash Flow Items, Total	224	-389	-694	-62	195
Cash From Financing Activities	-2031	-6823	-6465	-5035	-3740
Financing Cash Flow Items	-840	-1047	-1047	-997	-997
Total Cash Dividends Paid	-3047	-4364	-4364	-2971	-2971
Issuance (Retirement) of Stock, Net	4	29	11	8	5
Issuance (Retirement) of Debt, Net	1852	-1441	-1065	-1075	223
Foreign Exchange Effects	-11	-80	-86	-35	-9
Net Change in Cash	-155	-55	-1852	-1558	-685

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AstraZeneca - GBP Company profile

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

Industry:

Pharmaceuticals (NEC)

1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024